Showing results (51-60 of 129) with videos related to
Sort By:
Pageof 13
Cancer Chemotherapy and Pharmacology|January 8, 2021
Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.Blood|November 7, 2007
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disordersElizabeth O Hexner, Cynthia Serdikoff, Mahfuza Jan, et al.Cancer Genetics|April 29, 2021
Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AMLRobyn T Sussman, Bryan Manning, Daniel Ackerman, et al.Drugs in R&D|September 24, 2024
Trametinib Sensitivity is Defined by a Myeloid Differentiation Profile in Acute Myeloid LeukemiaMathieu Quesnel-Vallières, David C Schultz, Alena Orlenko, et al.Journal of Clinical Pharmacology|June 30, 2020
Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid LeukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.Experimental Hematology|June 28, 2011
Diagnostic microRNAs in myelodysplastic syndromeBegum Erdogan, Crystal Facey, Julianne Qualtieri, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 2, 2016
Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell TransplantationMarlise R Luskin, Martin Carroll, David Lieberman, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2004
Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cellsSteven J Bensinger, Patrick T Walsh, Jidong Zhang, et al.Blood|November 5, 2005
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulationDavid L Porter, Bruce L Levine, Nancy Bunin, et al.Blood Advances|March 19, 2024
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemiaMark Levis, Alexander Perl, Gary Schiller, et al.Pageof 13